Inverse association between raf kinase inhibitory protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: Implications for clinical outcome

Clinical Cancer Research

Volumn 14, Issue 10, 2008, Pages 2994-3001

  Chatterjee, Devasis ^a,b,c   Sabo, Edmond ^b,c   RosemarieTavares, ^b   Resnick, Murray B ^b,c  

^a Departments of Medicine   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; STAT3 PROTEIN; PEBP1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY; ADENOCARCINOMA; BIOSYNTHESIS; GENE EXPRESSION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; STOMACH TUMOR;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROGNOSIS; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 49649114120     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4496     Document Type: Article

References (50)

1. Mitelman F. Catalogue of chromosome aberrations in cancer. Cytogenet Cell Genet 1983;36:1-515.
2. Cancer Facts and Figures, American Cancer Society, 2004.
3. Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol 1996;23:281-91.
4. Desai AM, Pareek M, Nightingale PG, Fielding JW. Improving outcomes in gastric cancer over 2 years. Gastric Cancer 2004;7:196-201.
5. SEER Cancer Statistics Review 1975-2000, National Cancer Institute (NCI).
6. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-43.
7. Tahara E, Semba S, Tahara H. Molecular biological observations in gastric cancer. Semin Oncol 1996;23:307-15.
8. Wu MS, Shun CT, Wang HP, et al. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology 1997;112:1457-65.
9. Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E. Genetic and epigenetic alterations in multi-step carcinogenesis of the stomach. J Gastroenterol 2000;35:111-5.
10. Werner M, Becker KF, Keller G, Hofler H. Gastric adenocarcinoma: pathomorphology and molecular pathology. J Cancer Res Clin Oncol 2001;127:207-16.
11. Park WS, Oh RR, Park JY et al. Somatic mutations of the trefoil factor family 1 gene in gastric cancer Gastroenterology 2000;119:691-8.
12. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113-24.
13. Gong W.Wang L, Yao JC, et al. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin Cancer Res 2005;11:1386-93.
14. Bromberg JF, Wrzeszczynska MH, Devgan G, et al Stat3 as an oncogene. Cell 1999;98:295-303.
15. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54.
16. Kanda N, Seno H, Konda Y, et al STAT3 is constitu- tively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004;23:4921-9.
17. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2005;4:97-105.
18. Simister PC, Banfield MJ, Brady RL. The crystal structure of PEBP-2, a homologue of the PEBP/RKIP family. Acta Crystallogr D Biol Crystallogr 2002;58:1077-80.
19. Yeung K, Janosch P, McFerran B, et al Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol 2000;20:3079-85.
20. Yeung KC, Rose DW, Dhillon AS, et al. Raf kinase inhibitor protein interacts with NF-KB-inducing kinase and TAK1 and inhibits NF-kB activation. Mol Cell Biol 2001;21:7207-17.
21. Chatterjee D, Bai Y Wang Z, et al. RKIP sensitizes prostate and breast cancer cells to drug-induced apo- ptosis. J Biol Chem 2004;279:17515-23.
22. Fu Z, Kitagawa Y Shen R, et al. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 2006;66:248-56.
23. Hagan S, Al-Mulla F, Mallon E, et al. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res 2005;11:7392-7.
24. Minoo P, Zlobec I, Baker K, et al. Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am J Clin Pathol 2007;127:820-7.
25. Al-Mulla F, Behbehani Al, Bitar MS, et al. Genetic profiling of stage I and II colorectal cancer may predict metastatic relapse. Mod Pathol 2006:19:648-58.
26. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 2004;64:5186-92.
27. Darnowski JE, Goulete FA, Guan Y-J, et al. Stat3 cleavage by caspases impact on full-length Stat3 expression, fragment formation, and transcriptional activity. J Biol Chem 2006;281:17707-17.
28. Greene FL, Page OL, Fleming ID. AJCC: Cancer Staging Handbook: From The AJCC Cancer Staging Manual. 6th ed. New York (NY): Springer: 2002.
29. Resnick MB, Gavilanez M, Newton E, et al. Claudin expression in gastric adenocarinomas.a tissue microarray study with prognostic correlation Hum Pathol 2005;26:886-92.
30. Yuan PZ. Guan AY, Chatterjee D, Chin YE. Reversible acetylation of a single lysine residue within the C-ter- minal region of STAT3 regulates STAT3 dimerization Science 2005;307:269-73.
31. Tan K-B, PuttiTC. Potential implications carcinoma immunohistochemical findings and cyclooxygenase 2 expression in nasopharyngeal. J Clin Pathol 2005;58:535-8.
32. Yeung K, SeitzT, Li S, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP Na- ture1999;401:173-7.
33. Reed JC. Apoptosis-targeted therapies for cancer Cancer Cell 2003;3:17-22.
34. Oebatin KM, Krammer PH Death receptors in chemotherapy and cancer. Oncogene 1992;23:2950-66.
35. Correa P. Human gastric carcinogenesis: a multistep and multi-factorial process Cancer Res 1992;52:6735-40.
36. Zheng L.Wang L, Ajani J, Xie K. Molecular basis of gastric cancer development and progression Gastric Cancer 2004;7:61-77.
37. Fu Z, Smith PC, Zhang L, et al Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Nat Cancer Inst 2003;95:878-83.
38. Sasaki N, Morisaki T Hashizume K, et al. Nuclear factor-kB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 2001;7:4136-42.
39. Uetsuka H, Haisa M, Kimura M. et al. Inhibition of inducible NF-kB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line Exp Cell Res 2003;289:27-35.
40. Xiao W, Hodge DR.Wang L.Yang X, Zhang X. Farrar WL. Co-operative functions between nuclear factor NfkB and CCAT/enhnacer-binding protein (C/EBP-β regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 2004;61:354-70.
41. De Vita F, Romano C, Orditura M, et al. lnterleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 2001;21:45-52.
42. Wu CW.Wang SR, Chao MR et al. Serum mterleu-kin-6 levels reflect disease status of gastric cancer Am J Gastroenterol 1996;91:1417-22.
43. Yu LF, ChengY Qiao MM, ZhangYP.WuYL Activation of STAT3 signaling in human stomach adenocarcinoma drug-resistant cell line and its relationship with expression of vascular endothelial growth factor. World J Gastroenterol 2005;11:875-9.
44. Jenkins BJ, Grail D, NheuT, et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyper-proliferation and desensitizes TGF-H signaling. Nat Med 2005;11:845-52.
45. Catlett-Falcone R, LandowskiTH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15.
46. Gao B, Shen X, Kunos G, et al. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett 2001;488: 179-84.
47. Schindler C, Darnell JE, Jr.Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995;64:621-51.
48. Ni Z, Lou W, Leman ES, Gao AC. Inhibition of con-stitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 2000;60:1225-8.
49. Chatterjee D, Yuan Z, Bonavida B, Darnowski J, Chin E. RKIP inhibits IL-6 mediated activation of STAT 3 in prostate cancer cells. Proc Am Assoc Cancer Res 46;962:2005.
50. Chatterjee D, Sabo E, Resnick MB.Yeung KY Chin YE. The roles of RKIP and STAT3 in cancer chemotherapy: opposites attract: from sensitization of cancer cells for chemo/immuno/radiotherapy. Totowa (NJ). Humana Press. In press 2008.